4-tert-pentyl-phenetole | 92101-17-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-tert-pentyl-phenetole
• 英文别名: 4-tert-Pentyl-phenetol；4-tert.-Pentyl-phenetol；p-t-Pentylphenetole；1-ethoxy-4-(2-methylbutan-2-yl)benzene
• CAS: 92101-17-2
• 化学式: C₁₃H₂₀O
• 分子量: 192.301
• InChiKey: GQXZVIPLJDJUNN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  对叔戊基苯酚 生成 4-tert-pentyl-phenetole
  参考文献：
  名称：

  Engineering of aSagiyama AlphavirusRNA-Based Transient Expression Vector

  摘要：

  AbstractSagiyama virus (SAGV), a strain of Getah virus in the genus Alphavirus in the family Togaviridae, has a broad host range in vertebrates and invertebrates but is not pathogenic for humans. We engineered the SAGV genome as an efficient transient expression vector using the full‐length infectious cDNA clone pSAG2 as the background. A green fluorescent protein (GFP) gene was used as a reporter gene and expressed from a subgenomic mRNA. When the GFP gene was placed downstream of the intact capsid protein gene or an internally deleted capsid protein gene encoding the N‐terminal 9 amino acids and C‐terminal 149 amino acids, autoproteolysis occurred efficiently at the boundary site to release GFP from the N‐terminally‐fused capsid‐protease domain. GFP was also expressed efficiently without the 5′‐terminal region of the capsid protein gene, suggesting that SAGV capsid protein gene does not have a translation enhancer sequence. To provide structural proteins for pseudovirion formation, a nonviable mutant construct, pSAG2.3L, which contains a Gly‐to‐Leu substitution at the − 2 position of the nsP3/4 cleavage site, was used as a helper. GFP was expressed up to 50 μg from 1 × 106 BHK21 cells after inoculation of pseudovirions. The C6/36 mosquito cell was also a suitable host for a large scale expression of GFP using pseudovirions. In addition to high‐level transient expression, safeness of SAGV should give an advantage over other alphavirus expression vectors.

  DOI：

  10.1111/j.1348-0421.2002.tb02668.x

文献信息

• DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS
  申请人：Molteni Valentina

  公开号：US20080139559A1

  公开（公告）日：2008-06-12

  Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.

  本文描述了包含二芳胺结构特征的化合物。还描述了制备这种化合物的方法，使用这种化合物调节c-kit受体活性的方法，以及包含这种化合物的药物组合物和药物。还描述了使用这种化合物、药物组合物和药物治疗和/或预防和/或抑制和/或改善与c-kit受体活性相关的病理和/或症状性疾病或状况的方法。
• Novel Piperazines, Pharmaceutical Compositions and Methods of Use Thereof
  申请人：Clark Roger B.

  公开号：US20120071652A1

  公开（公告）日：2012-03-22

  Disclosed are novel piperazine derivatives that act as agonists of the α7 nAChR. Also disclosed are pharmaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds.

  本发明涉及新型哌嗪衍生物，其作为α7 nAChR的激动剂。本发明还涉及制药组合物、治疗炎症性疾病的方法、治疗中枢神经系统疾病的方法、抑制哺乳动物细胞细胞因子释放的方法以及制备新型化合物的方法。
• Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10399932B2

  公开（公告）日：2019-09-03

  There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

  本发明公开了调节或抑制吲哚胺-2,3-二氧化酶（IDO）酶活性的式(I)化合物、含有所述化合物的药物组合物以及利用本发明化合物治疗增殖性疾病（如癌症、病毒感染和/或炎症性疾病）的方法。
• METHOD OF PREPARING LITHOGRAPHIC PRINTING PLATE
  申请人：Taguchi Yoshinori

  公开号：US20100081771A1

  公开（公告）日：2010-04-01

  A method for preparing a lithographic printing plate includes treating a lithographic printing plate precursor including a hydrophilic support and an image-forming layer containing the following (i) to (iii) with an aqueous solution having a buffering ability: (i) a binder polymer comprising a repeating unit having a structure represented by the following formula (1); (ii) an ethylenically unsaturated compound; and (iii) a polymerization initiator, P-L-(CO 2 H) n (1) wherein P represents a part constituting a main chain skeleton of the polymer, L represents an (n+1) valent connecting group, and n represents an integer of 1 or more.
• BRUSH COMPOSITION AND METHOD OF PRODUCING STRUCTURE CONTAINING PHASE-SEPARATED STRUCTURE
  申请人：TOKYO OHKA KOGYO CO., LTD.

  公开号：US20160194524A1

  公开（公告）日：2016-07-07

  A brush composition used for phase-separation of a layer containing a block copolymer on a substrate, the brush composition including a resin component (N), the resin component (N) containing a hydrophobic structural unit (Nx) and a hydrophilic structural unit (Ny), the amount of the structural unit (Ny) within the resin component (N) being 5 mol % or less.